Innovative Science Solutions (ISS) is a consulting firm with over two decades of experience in the regulatory industry.
Innovative Science Solutions (ISS) is a consulting firm with over two decades of experience in the regulatory industry. As one of the leaders in regulatory submissions and drug-related FDA Advisory Committee Meeting (AdComm) support, ISS has designed this blog to give you the most up to date information on a wide array of FDA topics. Our incredibly talented team will breakdown and provide expert insight that you won’t find anywhere else.
FDA Advisory Committee Meeting
Don’t miss the latest in FDA AdComms
Regulatory and Quality Standards
Be at the forefront of all industry standards
A one-stop shop for your FDA compliance needs
Subscribe today so you don’t miss out. And for more custom advice on how ISS can help you, contact email@example.com
Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more
FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more
One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more
US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us